Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27589834
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Cell-free DNA and next-generation sequencing in the service of personalized
medicine for lung cancer
#MMPMID27589834
Bennett CW
; Berchem G
; Kim YJ
; El-Khoury V
Oncotarget
2016[Oct]; 7
(43
): 71013-71035
PMID27589834
show ga
Personalized medicine has emerged as the future of cancer care to ensure that
patients receive individualized treatment specific to their needs. In order to
provide such care, molecular techniques that enable oncologists to diagnose,
treat, and monitor tumors are necessary. In the field of lung cancer, cell free
DNA (cfDNA) shows great potential as a less invasive liquid biopsy technique, and
next-generation sequencing (NGS) is a promising tool for analysis of tumor
mutations. In this review, we outline the evolution of cfDNA and NGS and discuss
the progress of using them in a clinical setting for patients with lung cancer.
We also present an analysis of the role of cfDNA as a liquid biopsy technique and
NGS as an analytical tool in studying EGFR and MET, two frequently mutated genes
in lung cancer. Ultimately, we hope that using cfDNA and NGS for cancer diagnosis
and treatment will become standard for patients with lung cancer and across the
field of oncology.
free
free
free
